Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.
- Trial name
- BRE-08 (NCT06085742)
- Testing
- Cyclophosphamide, Methotrexate, Capecitabine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Illinois Chicago
Ovarian Epithelial Cancer, Carcinoma in Situ
Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing
In Phase I the sponsor will systematically test conditions for lavage filtration that increase tumor cell fraction without reducing tumor mutation yield.
- Conditions
- Ovarian Epithelial Cancer, Carcinoma in Situ, Ovarian Cancer
- Trial name
- EHUD (NCT04823871)
- Testing
- Speiser-catheter for uterine and tubal lavage
- Where
- 9 sites in Austria, Czechia and 2 more
- Volunteers
- 406 people
- Sponsor
- Paul Speiser, Prof.MD,
Untreated Operable Early Breast Cancer
Randomized Phase II Study to Assess PD 0332991 in Breast Cancer
This is a Phase II study trying to identify whether short term treatment with PD0332991 yields anti-proliferative response -defined by a low level of Ki67 expression (IHC) at surgery- or induces senescence as determined by SABG…
- Trial name
- POP (NCT02008734)
- Testing
- PD0332991
- Where
- France
- Volunteers
- 132 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Early Breast Cancer
Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
Evaluating the safety, tolerability and efficacy of Aromasin® when used in routine clinical practice, evaluating adherence to prescribed Aromasin® treatment and to understand reasons for early discontinuation.
- Trial name
- NCT01155063
- Testing
- Aromasin (exemestane)
- Volunteers
- 89 people
- Sponsor
- Pfizer
Breast Neoplasms
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer…
- Trial name
- SafeHER (NCT01566721)
- Testing
- Herceptin
- Where
- 437 sites in Albania, Algeria and 57 more
- Volunteers
- 2,577 people
- Sponsor
- Hoffmann-La Roche
Early Breast Cancer (Phase 2), Advanced Breast Cancer (Phase 1b)
Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer
PF-04691502 is an inhibitor of PI3K and mTOR kinase. Published data support the hypothesis that a PI3K/mTOR antagonist in combination with letrozole might mitigate the intrinsic or acquired resistance to hormonal therapy and…
- Trial name
- NCT01430585
- Testing
- PF-04691502, PF-04691502 in combination with Letrozole, Letrozole
- Where
- 5 sites in Belgium, Italy and 2 more
- Volunteers
- 14 people
- Sponsor
- Pfizer
Breast Cancer
Percutaneous Cryoablation of Low-risk Early Breast Cancer
Expand the current evidence base regarding percutaneous cryoablation of early-stage, low-risk breast tumors, integrated into the standard therapeutic pathway with well-defined follow-up data, as well as data on quality of life.
- Trial name
- PRECICE (NCT06300125)
- Testing
- Cryoablation
- Where
- Italy
- Volunteers
- 234 people
- Sponsor
- European Institute of Oncology
Braest Cancer, Breast Reconstruction
Evaluating the Effectiveness of an Early Exercise Program After Breast Reconstruction
Breast reconstruction is an important step and option after mastectomy and can help improve the quality of life of breast cancer patients.
- Trial name
- NCT06552650
- Testing
- Exercise, Usual Care
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Early-stage Breast Cancer, Breast Cancer Female
The ConnectedCancerCare Pilot Study (CCC)
This study is an NCI-funded, randomized control pilot trial to evaluate: (1) the feasibility and acceptability of a web-based, personalized navigation tool (ConnectedCancerCare) and (2) explore whether the tool improves delivery…
- Conditions
- Early-stage Breast Cancer, Breast Cancer Female, Survivorship, Cancer Survivors
- Trial name
- CCC (NCT03618017)
- Testing
- CCC website, Static care plan
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Michigan Rogel Cancer Center
Breast Cancer
Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00712140
- Testing
- trastuzumab, parenteral chemotherapy
- Where
- 11 sites in United Kingdom
- Volunteers
- 4,000 people
- Sponsor
- Warwick Medical School
Fatigue, Depression
Adaptive Symptom Care Using Fish-Based Nutritional Directives Post Breast Cancer
Inflammation has been consistently associated with psychoneurological symptoms (PNS) among breast cancer survivors (BCS). Evidence supporting interventional strategies promoting symptom-self management in reducing…
- Conditions
- Fatigue, Depression, Pain, Sleep Disturbance
- Trial name
- NCT04293874
- Testing
- Personalized Meal Plan, Dietary Omega-3LC intervention
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- University of Connecticut
Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)
A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer
This Phase 3 study will evaluate whether atirmociclib plus giredestrant improves invasive breast cancer-free survival compared with giredestrant alone in adults with ER-positive, HER2-negative early breast cancer at medium or…
- Trial name
- NCT07890597
- Testing
- Atirmociclib, giredestrant
- Volunteers
- 3,800 people
- Sponsor
- Pfizer
Breast Cancer Stage I, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
CRYO-1: Cryoablation in Elderly Patients With Early-Stage Breast Cancer.
This study looks at a new way to treat early-stage breast cancer in older adults using a freezing technique called cryoablation.
- Trial name
- CRYO-1 (NCT07398118)
- Testing
- Cryoablation / Cryotherapy
- Where
- 3 sites in Netherlands
- Volunteers
- 61 people
- Sponsor
- St. Antonius Hospital
Early Breast Cancer
A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity
Taxane-induced peripheral neuropathy (TIPN) caused by paclitaxel is a dose-limiting toxicity. The main symptoms of discomfort are numbness, tingling, and burning sensations in the glove-sock-like distribution of the limbs.
- Trial name
- NCT04222790
- Testing
- monosialic gangliosides
- Where
- China
- Volunteers
- 159 people
- Sponsor
- Henan Cancer Hospital
Early Stage HER2+ Breast Cancer
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Loperamide or other prophylactic measures.
- Trial name
- NCT02400476
- Testing
- Neratinib, Loperamide, Colestipol
- Where
- 58 sites in United States, Australia and 5 more
- Volunteers
- 563 people
- Sponsor
- Puma Biotechnology, Inc.
HER2-positive Breast Cancer
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
This is a randomised, double-blind multicenter Phase III study for evaluating the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus docetaxel versus placebo and trastuzumab plus docetaxel given as neoadjuvant…
- Trial name
- NCT03588091
- Testing
- Pyrotinib, Trastuzumab, Docetaxel
- Where
- 17 sites in China
- Volunteers
- 355 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
This phase II trial studies how well anastrozole and letrozole after surgery work in treating patients with stage I-III breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04294225
- Testing
- Anastrozole, Letrozole
- Where
- 3 sites in United States
- Volunteers
- 161 people
- Sponsor
- Mayo Clinic
Breast Cancer
Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer
In the proposed project the investigators will asses whether changes in expression of selected circulating microRNAs in serum could comprise a sensitive and specific biomarker of cardiotoxicity in cancer patients treated with…
- Trial name
- NCT02065908
- Where
- 3 sites in Poland
- Volunteers
- 128 people
- Sponsor
- West Pomeranian Cancer Center
Breast Cancer
Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)
This is a randomized, open-label, multicenter, phase III study comparing anthracyclines followed by taxane to anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast…
- Trial name
- NCT02441933
- Testing
- taxane plus carboplatin, Taxane
- Where
- 21 sites in South Korea
- Volunteers
- 878 people
- Sponsor
- Yonsei University
HER2-positive Early Breast Cancer
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients
Neoadjuvant treatment is an important treatment for early breast cancer patients. Patients with her2 enriched subtype who achieved pCR after neoadjuvant treatment would have longer survival.
- Trial name
- NCT04750122
- Testing
- neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking University People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.